NCT03856541View on ClinicalTrials.gov

A Study of SHR-A1403 in Patients With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

December 30, 2019

Study Completion Date

May 7, 2020

Conditions
Advanced Solid Tumor
Interventions
DRUG

SHR-A1403

SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min

Trial Locations (1)

200032

Shanghai Cancer Center, Fudan University, Shanghai

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03856541 - A Study of SHR-A1403 in Patients With Advanced Solid Tumor | Biotech Hunter | Biotech Hunter